Cassady Schiller Wealth Management’s Amicus Therapeutics FOLD Stock Holding History

Cassady Schiller Wealth Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$414	Buy	+44	New	+$457	﹤0.01%	1014

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cassady Schiller Wealth Management's FOLD Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Amicus Therapeutics (FOLD) in Q4 2024: 44 shares worth $414. The stake represents ﹤0.01% of the portfolio and ranks #1014 among its holdings.

290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

Cassady Schiller Wealth Management held 44 shares of Amicus Therapeutics worth $414 as of Q4 2024.
Amicus Therapeutics was a new Cassady Schiller Wealth Management position in Q4 2024.
Amicus Therapeutics made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #1014 holding.
290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.